Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan

Yagi, Asami; Nakagawa, Satoshi; Ueda, Yutaka; Oka, Emiko; Ikeda, Sayaka; Kakuda, Mamoru; Kobayashi, Eiji; Ito, Yuri; Katayama, Kayoko; Hirai, Kei; Nakayama, Tomio; Kimura, Tadashi

doi:https://doi.org/10.1111/cas.16055

Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan

Yagi, Asami; Nakagawa, Satoshi; Ueda, Yutaka et al.

Cancer Science, 2024, 115(3), 916-925

Number of Access:1,873（2025-07-18 17:03 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/94883

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
CancerSci_115_3_916	pdf	None	4.69 MB	418	2024.04.08

Creative Commons : Attribution - NonCommercial

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan
Creator	NRID 1000030793450 1000030793450 researchmap permalink 2018101510006244 2018101510006244 Scopus Author ID 56244059700 56244059700 CreatorName Yagi, Asami
	NRID 1000030650593 1000030650593 ORCID 0000-0001-6540-9040 0000-0001-6540-9040 researchmap permalink snakagawa snakagawa Scopus Author ID 56514567200 56514567200 CreatorName Nakagawa, Satoshi
	NRID 1000010346215 1000010346215 ORCID 0000-0001-8760-6379 0000-0001-8760-6379 researchmap permalink read0092318 read0092318 Scopus Author ID 55087087500 55087087500 CreatorName Ueda, Yutaka
	CreatorName Oka, Emiko
	NRID 1000040818902 1000040818902 CreatorName Ikeda, Sayaka
	NRID 1000030923031 1000030923031 researchmap permalink mamorukakuda mamorukakuda Scopus Author ID 56692693900 56692693900 CreatorName Kakuda, Mamoru
	NRID 1000050614773 1000050614773 CreatorName Kobayashi, Eiji
	NRID 1000060585305 1000060585305 CreatorName Ito, Yuri
	NRID 1000070584374 1000070584374 CreatorName Katayama, Kayoko
	NRID 1000070294014 1000070294014 researchmap permalink keihirai keihirai Scopus Author ID 36056438100 36056438100 CreatorName Hirai, Kei
	NRID 1000060501822 1000060501822 CreatorName Nakayama, Tomio
	NRID 1000090240845 1000090240845 researchmap permalink read0106368 read0106368 Scopus Author ID 35421281200 35421281200 CreatorName Kimura, Tadashi
Subject	cervical cancer
	health communication
	HPV vaccine
	Japan
	suspension of recommendation
Description	Yagi A., Nakagawa S., Ueda Y., et al. Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan. Cancer Science 115, 916 (2024); https://doi.org/10.1111/cas.16055.
Abstract	In 2013, the national human papillomavirus (HPV) immunization program began. However, in June 2013, Japan's Ministry of Health, Labor and Welfare (MHLW) announced a “temporary” suspension of its recommendation for the human papillomavirus vaccine. Finally, in November 2021, the MHLW ended its suspension of the recommendation of the HPV vaccine. To address the 9-year gap in HPV vaccinations the suspension had caused, the MHLW conducted a program of catch-up vaccinations from April 2022 to March 2025. Finally, in April 2023, the 9-valent HPV vaccine was approved for both the routine and catch-up vaccination programs in Japan. In this study, we investigated the potential effects of the introduction of the 9-valent vaccine on the increased risk of cervical cancer in females born after fiscal year (FY) 2000. We estimated the lifetime relative risk of cervical cancer incidence and death using the improved routine and catch-up vaccination rates after the recent resumption of the governmental recommendation for women and girls to have the HPV vaccination. These relative risks were calculated using a lifetime risk of 1.000 for cervical cancer incidence and death for females born in FY 1993. We predicted that even if a 90% vaccination rate were to be achieved by FY 2024 with the 9-valent vaccine among women born between FY 2000 and FY 2005, the risk would remain higher than for the vaccination generation. Therefore, for women born between FY 2000 and FY 2005, it will be necessary to significantly improve the cervical cancer screening rate to compensate for this increased risk.
Publisher	John Wiley and Sons Inc
Source Title	Cancer Science
Volume (Issue)	115(3)
Page	916-925
Date of Issued	2024-03-01
Language	English
Handle URL	https://hdl.handle.net/11094/94883
PISSN	13479032
eISSN	13497006
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1111/cas.16055
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Cancer Science. 2024, 115(3), p. 916-925
DC.title	Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan
DC.creator	Yagi, Asami
	Nakagawa, Satoshi
	Ueda, Yutaka
	Oka, Emiko
	Ikeda, Sayaka
	Kakuda, Mamoru
	Kobayashi, Eiji
	Ito, Yuri
	Katayama, Kayoko
	Hirai, Kei
	Nakayama, Tomio
	Kimura, Tadashi
DC.publisher	John Wiley and Sons Inc
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-03-01
DC.identifier	https://doi.org/10.1111/cas.16055
DC.subject	cervical cancer
	health communication
	HPV vaccine
	Japan
	suspension of recommendation
DC.description	Yagi A., Nakagawa S., Ueda Y., et al. Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan. Cancer Science 115, 916 (2024); https://doi.org/10.1111/cas.16055.
DCTERMS.abstract	In 2013, the national human papillomavirus (HPV) immunization program began. However, in June 2013, Japan's Ministry of Health, Labor and Welfare (MHLW) announced a “temporary” suspension of its recommendation for the human papillomavirus vaccine. Finally, in November 2021, the MHLW ended its suspension of the recommendation of the HPV vaccine. To address the 9-year gap in HPV vaccinations the suspension had caused, the MHLW conducted a program of catch-up vaccinations from April 2022 to March 2025. Finally, in April 2023, the 9-valent HPV vaccine was approved for both the routine and catch-up vaccination programs in Japan. In this study, we investigated the potential effects of the introduction of the 9-valent vaccine on the increased risk of cervical cancer in females born after fiscal year (FY) 2000. We estimated the lifetime relative risk of cervical cancer incidence and death using the improved routine and catch-up vaccination rates after the recent resumption of the governmental recommendation for women and girls to have the HPV vaccination. These relative risks were calculated using a lifetime risk of 1.000 for cervical cancer incidence and death for females born in FY 1993. We predicted that even if a 90% vaccination rate were to be achieved by FY 2024 with the 9-valent vaccine among women born between FY 2000 and FY 2005, the risk would remain higher than for the vaccination generation. Therefore, for women born between FY 2000 and FY 2005, it will be necessary to significantly improve the cervical cancer screening rate to compensate for this increased risk.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	94883
citation_title	Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan
citation_author	Yagi, Asami
	Nakagawa, Satoshi
	Ueda, Yutaka
	Oka, Emiko
	Ikeda, Sayaka
	Kakuda, Mamoru
	Kobayashi, Eiji
	Ito, Yuri
	Katayama, Kayoko
	Hirai, Kei
	Nakayama, Tomio
	Kimura, Tadashi
citation_publisher	John Wiley and Sons Inc
citation_language	English
citation_date	2024-03-01
citation_journal_title	Cancer Science
citation_volume	115
citation_issue	3
citation_firstpage	916
citation_lastpage	925
citation_doi	https://doi.org/10.1111/cas.16055
citation_public_url	https://hdl.handle.net/11094/94883

Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan

Link to primary information

Item Information

Show details